The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia

Current Opinion in Oncology

Volumn 20, Issue 6, 2008, Pages 690-696

  Levy, Benjamin ^a   Arnason, Jon E ^a   Bussel, James B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bleeding; Hepatitis c; Immune thrombocytopenia purpura; Platelets; Thrombopoietin

Indexed keywords

AKR 501; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ELTROMBOPAG; FAB 59; LBGB4665; MA01G4G344; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; MEGAKARYOCYTE GROWTH FACTOR; PEG TPOMP; PEGINTERFERON; PLACEBO; REMIPLISTIM; RIBAVIRIN; THROMBOPOIETIN; UNCLASSIFIED DRUG; VB22B;

ABDOMINAL PAIN; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTUSION; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; HEADACHE; HEPATITIS C; HUMAN; IMMUNE RESPONSE; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING;

BENZOIC ACIDS; BLOOD PLATELETS; CARRIER PROTEINS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HEMORRHAGE; HEPATITIS C; HUMANS; HYDRAZINES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; THROMBOCYTOPENIA; THROMBOPOIESIS; TREATMENT OUTCOME;

EID: 55749105715     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32831369b2     Document Type: Review

References (30)

1. Perry M. The chemotherapy source book. In: Pine J, editor. Hematopoeitic growth factors. Philadelphia: Lippincott William and Wilkins; 20Oa pp. 44-51.
2. Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82:1395-1401.
3. Debili N, Wendling F, Katz A, et al. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 1995; 86:2516-2525.
4. Nichol JL. The Mpl ligand and platelet homeostasis. Acta Paediatr Suppl 1998; 424:7-15.
5. Somlo G, Sniecinski I, ter Veer A, et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood 1999; 93:2798-2806.
6. Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997; 89:3118-3128.
7. Basser RL, Rasko JE, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348:1279-1281.
8. Basser RL, Underhill C, Davis I, et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol 2000; 18:2852-2861.
9. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycolconjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336:404-409.
10. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000; 132:364-368.
11. Archimbaud E, Ottmann OG, Yin JA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999; 94:3694-3701.
12. Bolwell B, Vredenburgh J, Overmoyer B, et al. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) In breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 2000; 26:141-145.
13. Nash RA, Kurzrock R, DiPersio J, et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2000; 6:25-34.
14. Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000; 95:2530-2535.
15. Komatsu N, Okamoto T, Yoshida T, et al. Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts (PLT) in patients (pts) with aplastic anemia (AA) and myelodysplastic syndrome (MDS) [abstract]. Blood 2000; 96:296a.
16. Harker LA, Carter RA, Marzec UM, et al. Correction of thrombocytopenia and ineffective platelet production in patients with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy. Blood 1998; 92:707a.
17. Nomura S, Dan K, Hotta T, et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002; 100:728-730.
18. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002; 99:2599-2602.
19. Li J, Xia Y, Bertino A, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241-3248.
20. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76:628-638.
21. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355:1672-1681. The first phase I/II trial in which patients with chronic ITP receiving AMG 531 had a dose-dependent increase in platelet count with minimal side affects reported.
22. Newland A, Caulier MT, Kappers-Klunne M, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006; 135:547-553.
23. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371395-403. The first (two) parallel, randomized, double-blinded, placebo-controlled phase III trials in which 63 splenectomized and 62 nonsplenectomized patients with (TP were randomly assigned 2:1 subcutaneous injections of romiplostim or placebo every week for 24 weeks. This trial demonstrated an increased overall platelet response and a reduction in current therapy for both splenectomized and nonsplenectomized patients when compared with placebo.
24. Bussel JB, Kuter DJ, de Wolf JThM, et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 2-year update [abstract number 568], Blood (ASH Annual Meeting Abstracts) 2007; 110:174a Phase I/II study in which 28 patients with low-risk MDS received three weekly doses of AMG 531 for at least 4 weeks. Patients demonstrated increased median peak platelet counts during the 4-week treatment period, with almost half who completed 12 weeks of treatment achieving a durable platelet response. 25 Kantajian HM. Evaluating safety and efficacy of AMG 531 for the treatment of thrombocytopenic patients with myelodysplastic syndrome (MDS): preliminary results of a phase 1/2 study. American Society of Clinical Oncology Annual Meeting; Chicago, Illinois; 2007.
25. Kantarjian H, Fenaux P, Sekeres MA, et al. Phase 1/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): update including extended treatment [abstract number 250]. Blood (ASH Annual Meeting Abstracts) 2007; 110:81a.
26. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109:4739-4741. Phase I placebo-controlled clinical trial, 73 healthy male individuals were administered eltrombopag as once daily oral capsules and demonstrated dose-dependent increase in platelets and safety.
27. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357:2227-2236. Phase II placebo-controlled randomized clinical trial, 74 patients with HCV-related cirrhosis and thrombocytopenia randomly assigned to receive eltrombopag or placebo daily for 4 weeks demonstrated a dose-dependent increase in platelets allowing a greater number of patients to complete treatment for HCV.
28. Bussel JB, Cheng G, Saleh MN, et al. Elrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357:2237-2247. Phase II placebo-controlled randomized clinical trial, 118 adults with chronic ITP and significant thrombocytopenia assigned to receive ertrombopag or placebo, demonstrated dose-dependent increase in platelets, decreased bleeding and minimal side effects.
29. Bussel JB, Provan A, Shamsi T, et al. Eltrombopag raises platelet count and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: a phase III study. European Hematology Association Abstract, 2007; 0390.
30. Douglas VK, Tallman MS, Cripe LD, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol 2002; 117:844-850.